A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD

Kidney International

Volumn 61, Issue 4, 2002, Pages 1469-1474

  Harris, Kevin P G ^a,b,c   Wheeler, David C ^a,b,c   Chong, Camilla C ^a,b,c  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Atorvastatin; CAPD; Chronic renal disease; Dyslipidemia; LDL cholesterol; Lipoprotein metabolism

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; HUMAN; HYPERVOLEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; PAIN; PERITONITIS; PRIORITY JOURNAL; PRURITUS; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

EID: 0036231334     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00262.x     Document Type: Article

References (19)

1. Clinical epidemiology of cardiovascular disease in chronic renal failure
2. Joint British recommendations on prevention of coronary heart disease in clinical practice
3. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
4. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
5. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES study)
6. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholester-olemia by atorvastatin, a new HMG-CoA reductase inhibitor
7. An overview of the clinical safety profile of atorvastatin (Lipitor) a new HMG-CoA reductase inhibitor
8. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
9. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia: Atorvastatin study group I
10. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
11. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin
12. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
13. Hyperlipidemia in patients with chronic renal disease
14. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis
15. The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: A double-blind, placebo-controlled trial in patients with ESRD
16. Statins and the kidney
17. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome
18. Lovastatin retards the progression of established glomerular disease in obese Zucker rats
19. Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis